Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena Defends Obesity Drug After Phase III BLOOM Wilts

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial

You may also be interested in...

Orexigen Starts Partnership Talks On Obesity Drug Contrave

Firm stresses Phase III efficacy results will pass muster with FDA.

Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes

CEO hails positive Phase III data, but not all analysts are convinced.

Obesity Guidance Should Be More Lenient On Indications, Firms Tell FDA

A stipulation that patients should fail lifestyle modifications before they are eligible to enroll in clinical trials for obesity drugs needs to be modified, according to industry comments on an FDA draft guidance on development of weight management drugs


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts